PDF(Pubmed)
Abstract：
Acute cerebral infarction (ACI) is a lethal disease whose early diagnosis is critical for treatment. microRNA (miR)-19a targets CC chemokine ligand 20 (CCL20) in myocardial infarction. We investigated the expression patterns of serum miR-19a and CCL20 of ACI patients and assessed their clinical values. Serum samples of 50 healthy subjects and110 ACI patients were collected. Serum levels of miR-19a, CCL20 mRNA, and biochemical indexes were assessed. miR-19a downstream target gene and the binding relationship between miR-19a and CCL20 were predicted and verified. miR-19a and CCL20 mRNA were subjected to correlation and diagnostic efficiency analysis. miR-19a was poorly expressed in the serum of ACI patients, especially in patients with unstable plaque and large infarction. tumor necrosis factor-α, low-density lipoprotein, and platelet/lymphocyte ratio negatively correlated with serum miR-19a level and positively correlated with CCL20. Dual-luciferase assay revealed that miR-19a could negatively regulate CCL20 expression. CCL20 was highly expressed in the serum of ACI patients. The area under receiver-operating characteristic curve of miR-19a combined with CCL20 was 0.9741 (98.00% specificity, 90.91% sensitivity), higher than their single diagnosis. Collectively, miR-19a had high diagnostic value for ACI and could target to restrain CCL20. The combination of miR-19a and CCL20 improved diagnostic value for ACI.
摘要：
急性脑梗死（ACI）是一种致死性疾病，其早期诊断对治疗至关重要。微小RNA(miR)-19a靶向心肌梗死中的CC趋化因子配体20(CCL20)。我们研究了ACI患者血清miR-19a和CCL20的表达模式，并评估了其临床价值。收集50例健康受试者和110例ACI患者的血清样本。血清miR-19a水平,CCL20mRNA,并对生化指标进行评估。对miR-19a下游靶基因及miR-19a与CCL20的结合关系进行预测和验证。对miR-19a和CCL20mRNA进行相关性和诊断效率分析。miR-19a在ACI患者血清中低表达,尤其是不稳定斑块和大面积梗死的患者。肿瘤坏死因子-α，低密度脂蛋白，血小板/淋巴细胞比值与血清miR-19a水平呈负相关,与CCL20呈正相关。双荧光素酶检测显示miR-19a可以负调控CCL20的表达。CCL20在ACI患者血清中高表达。miR-19a联合CCL20的受试者工作特征曲线下面积为0.9741(98.00%特异性,90.91%灵敏度)，高于其单一诊断。总的来说，miR-19a对ACI有较高的诊断价值,可以靶向克制CCL20。miR-19a和CCL20的组合提高了对ACI的诊断价值。
